Vitamin D insufficiency and musculoskeletal symptoms in breast cancer survivors on aromatase inhibitor therapy

Nancy Lauraine Waltman, Carol D. Ott, Janice J Twiss, Gloria J. Gross, Ada M. Lindsey

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Breast cancer survivors (BCSs) on aromatase inhibitor (AI) therapy often experience musculoskeletal symptoms (joint pain and stiffness, bone and muscle pain, and muscle weakness), and these musculoskeletal symptoms may be related to low serum levels of vitamin D. The primary purpose of this pilot exploratory study was to determine whether serum levels of 25-hydroxyvitamin D (25[OH]D) concentration were below normal (<30 ng/mL) in 29 BCSs on AI therapy and if musculoskeletal symptoms were related to these low vitamin D levels. The mean (SD) serum 25(OH)D level was 25.62 (4.93) ng/mL; 86% (n = 25) had levels below 30 ng/mL. Patients reported muscle pain in the neck and back, and there was a significant inverse correlation between pain intensity and serum 25(OH)D levels (r = -0.422; P < .05 [2 tailed]). This sample of BCSs taking AIs had below normal levels of serum 25(OH)D despite vitamin D supplements. This is one of the few studies to document a significant relationship between vitamin D levels and muscle pain in BCSs on AI therapy. Findings from this pilot study can be used to inform future studies examining musculoskeletal symptoms in BCSs on AI therapy and relationships with low serum levels of vitamin D.

Original languageEnglish (US)
Pages (from-to)143-150
Number of pages8
JournalCancer Nursing
Volume32
Issue number2
DOIs
StatePublished - Mar 1 2009

Fingerprint

Aromatase Inhibitors
Vitamin D
Survivors
Breast Neoplasms
Myalgia
Serum
Therapeutics
Muscle Weakness
Arthralgia
Neck
Bone and Bones
Pain

Keywords

  • 25-Hydroxyvitamin D
  • Aromatase inhibitors therapy
  • Breast cancer
  • Musculoskeletal symptoms
  • Pilot exploratory study

ASJC Scopus subject areas

  • Oncology
  • Oncology(nursing)

Cite this

Vitamin D insufficiency and musculoskeletal symptoms in breast cancer survivors on aromatase inhibitor therapy. / Waltman, Nancy Lauraine; Ott, Carol D.; Twiss, Janice J; Gross, Gloria J.; Lindsey, Ada M.

In: Cancer Nursing, Vol. 32, No. 2, 01.03.2009, p. 143-150.

Research output: Contribution to journalArticle

@article{fc34a43da3b84161b71f5e7da0806de5,
title = "Vitamin D insufficiency and musculoskeletal symptoms in breast cancer survivors on aromatase inhibitor therapy",
abstract = "Breast cancer survivors (BCSs) on aromatase inhibitor (AI) therapy often experience musculoskeletal symptoms (joint pain and stiffness, bone and muscle pain, and muscle weakness), and these musculoskeletal symptoms may be related to low serum levels of vitamin D. The primary purpose of this pilot exploratory study was to determine whether serum levels of 25-hydroxyvitamin D (25[OH]D) concentration were below normal (<30 ng/mL) in 29 BCSs on AI therapy and if musculoskeletal symptoms were related to these low vitamin D levels. The mean (SD) serum 25(OH)D level was 25.62 (4.93) ng/mL; 86{\%} (n = 25) had levels below 30 ng/mL. Patients reported muscle pain in the neck and back, and there was a significant inverse correlation between pain intensity and serum 25(OH)D levels (r = -0.422; P < .05 [2 tailed]). This sample of BCSs taking AIs had below normal levels of serum 25(OH)D despite vitamin D supplements. This is one of the few studies to document a significant relationship between vitamin D levels and muscle pain in BCSs on AI therapy. Findings from this pilot study can be used to inform future studies examining musculoskeletal symptoms in BCSs on AI therapy and relationships with low serum levels of vitamin D.",
keywords = "25-Hydroxyvitamin D, Aromatase inhibitors therapy, Breast cancer, Musculoskeletal symptoms, Pilot exploratory study",
author = "Waltman, {Nancy Lauraine} and Ott, {Carol D.} and Twiss, {Janice J} and Gross, {Gloria J.} and Lindsey, {Ada M.}",
year = "2009",
month = "3",
day = "1",
doi = "10.1097/01.NCC.0000339262.44560.92",
language = "English (US)",
volume = "32",
pages = "143--150",
journal = "Cancer Nursing",
issn = "0162-220X",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Vitamin D insufficiency and musculoskeletal symptoms in breast cancer survivors on aromatase inhibitor therapy

AU - Waltman, Nancy Lauraine

AU - Ott, Carol D.

AU - Twiss, Janice J

AU - Gross, Gloria J.

AU - Lindsey, Ada M.

PY - 2009/3/1

Y1 - 2009/3/1

N2 - Breast cancer survivors (BCSs) on aromatase inhibitor (AI) therapy often experience musculoskeletal symptoms (joint pain and stiffness, bone and muscle pain, and muscle weakness), and these musculoskeletal symptoms may be related to low serum levels of vitamin D. The primary purpose of this pilot exploratory study was to determine whether serum levels of 25-hydroxyvitamin D (25[OH]D) concentration were below normal (<30 ng/mL) in 29 BCSs on AI therapy and if musculoskeletal symptoms were related to these low vitamin D levels. The mean (SD) serum 25(OH)D level was 25.62 (4.93) ng/mL; 86% (n = 25) had levels below 30 ng/mL. Patients reported muscle pain in the neck and back, and there was a significant inverse correlation between pain intensity and serum 25(OH)D levels (r = -0.422; P < .05 [2 tailed]). This sample of BCSs taking AIs had below normal levels of serum 25(OH)D despite vitamin D supplements. This is one of the few studies to document a significant relationship between vitamin D levels and muscle pain in BCSs on AI therapy. Findings from this pilot study can be used to inform future studies examining musculoskeletal symptoms in BCSs on AI therapy and relationships with low serum levels of vitamin D.

AB - Breast cancer survivors (BCSs) on aromatase inhibitor (AI) therapy often experience musculoskeletal symptoms (joint pain and stiffness, bone and muscle pain, and muscle weakness), and these musculoskeletal symptoms may be related to low serum levels of vitamin D. The primary purpose of this pilot exploratory study was to determine whether serum levels of 25-hydroxyvitamin D (25[OH]D) concentration were below normal (<30 ng/mL) in 29 BCSs on AI therapy and if musculoskeletal symptoms were related to these low vitamin D levels. The mean (SD) serum 25(OH)D level was 25.62 (4.93) ng/mL; 86% (n = 25) had levels below 30 ng/mL. Patients reported muscle pain in the neck and back, and there was a significant inverse correlation between pain intensity and serum 25(OH)D levels (r = -0.422; P < .05 [2 tailed]). This sample of BCSs taking AIs had below normal levels of serum 25(OH)D despite vitamin D supplements. This is one of the few studies to document a significant relationship between vitamin D levels and muscle pain in BCSs on AI therapy. Findings from this pilot study can be used to inform future studies examining musculoskeletal symptoms in BCSs on AI therapy and relationships with low serum levels of vitamin D.

KW - 25-Hydroxyvitamin D

KW - Aromatase inhibitors therapy

KW - Breast cancer

KW - Musculoskeletal symptoms

KW - Pilot exploratory study

UR - http://www.scopus.com/inward/record.url?scp=68149164579&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68149164579&partnerID=8YFLogxK

U2 - 10.1097/01.NCC.0000339262.44560.92

DO - 10.1097/01.NCC.0000339262.44560.92

M3 - Article

VL - 32

SP - 143

EP - 150

JO - Cancer Nursing

JF - Cancer Nursing

SN - 0162-220X

IS - 2

ER -